Results

Total Results: 2,890 records

Showing results for "disease".

341. Icd-Categories-Prevalence-Reimbursement Research (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/icd-categories-prevalence-reimbursement_research.pdf
     January 01, 2011 - disorders, hypertension, heart disease, pulmonary disorders, spine-related care, gastrointestinal upset … , and kidney disease.2,4,5,6 Chronic diseases disproportionately affect older adults.2 Among the Medicare … notable increases in recent spending are attributable to diabetes, chronic obstructive pulmonary disease … , kidney disease, hyperlipidemia, hypertension, mental disorders, and arthritis. … STUDY PERIOD The study period over which disease burden and costs were examined was 2006-2009.

342. Development of Quality Criteria To Evaluate Nontherapeutic Studies of Incidence, Prevalence, or Risk Factors of Chronic Diseases: Pilot Study of New Checklists | Effective Health Care Program
     effectivehealthcare.ahrq.gov/products/asthma-immunotherapy-2011
     February 01, 2011 - Quality Criteria To Evaluate Nontherapeutic Studies of Incidence, Prevalence, or Risk Factors of Chronic Diseases … Quality Criteria To Evaluate Nontherapeutic Studies of Incidence, Prevalence, or Risk Factors of Chronic Diseases

343. Progression-Free Survival: What Does It Mean for Psychological Well-Being or Quality of Life? | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/products/survival-quality/research
     April 12, 2013 - Progression-free survival (PFS), defined as the time from random assignment in a clinical trial to disease … range of potential biases, and its use as a surrogate for OS has been demonstrated only for certain disease … KQ2 sought to determine an association between PFS and QOL or related outcomes, such as disease symptoms … The four studies demonstrated better QOL or disease symptoms among patients who remained progression-free … compared with those who had disease progression.

344. Topic Suggestion Description | Effective Health Care Program
     effectivehealthcare.ahrq.gov/get-involved/nominated-topics/does-the-use-of-cytochrome-p450-2c19-cyp2c19-testing-to-predict-response-to-clopidogrel-in-people-1-with-acute-coronary-syndrome-2-who-have-suffered-other-cardiovascular-disease-related-events-eg-ischemic-stroke-symptomatic-p
     August 04, 2010 - events (e.g., ischemic stroke, symptomatic peripheral arterial disease), or (3) undergoing percutaneous … Patients with acute coronary syndrome, 2) patients who have suffered other cardiovascular disease-related … (For example, an ethnic group, stage or severity of a disease.) … (check all that apply) EHC Priority Conditions (updated in 2008) Cardiovascular disease, including … While clopidogrel may decrease morbidity and mortality associated with several cardiovascular diseases

345. Epstein_Respondent_Glasgow 1 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/interactive_media_epstein_respondent.pdf
     January 01, 2009 -     Slide  3:  What  are  the  “patient-­‐centered”  goals  of  IM-­‐supported  disease … consensual  decision-­‐ making   Slide  4:  To  what  degree  does  IM-­‐supported  disease …  patient  can  interpret  and  infer   • Tailored  information   o Tailored  to  disease … Slide  17:  From  disease  management  to  patient/family-­‐focused  health   enhancement … Slide  18:  Extensions   • How  can  the  lessons  from  chronic  disease  management

346. Future Research Needs for Hematopoietic Stem-Cell Transplantation in the Pediatric Population (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/stem-cell-children-future_research.pdf
     February 01, 2012 - See Appendix B for a list of conclusions by Key Question and disease and Appendix C for diseases where … Here, we focused on one intervention and multiple diseases and disease indications, presenting a challenge … Although the diseases may appear to be similar, the implications of both the disease and treatment on … Diseases that have both rapidly and slowly progressive forms of disease where outcomes are overall … "[Mesh]) OR "Lysosomal Storage Diseases"[Mesh]) OR "Glycogen Storage Disease"[Mesh]) OR "Niemann-Pick

347. Decision Modeling (ppt file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/medical-test-reviews-decision-modeling.ppt
     June 01, 2012 - can even be used to explore hypothetical scenarios such as hypothetical interventions for incurable diseases … The MISCAN simulation program for the evaluation of screening for disease. … Knowledge of the natural history of the disease may have changed. … of older modeling studies, which would in turn affect the parameters used in the underlying disease … The MISCAN simulation program for the evaluation of screening for disease.

348. Decision Modeling (ppt file)
     effectivehealthcare.ahrq.gov/sites/default/files/medical-test-reviews-decision-modeling.ppt
     June 01, 2012 - can even be used to explore hypothetical scenarios such as hypothetical interventions for incurable diseases … The MISCAN simulation program for the evaluation of screening for disease. … Knowledge of the natural history of the disease may have changed. … of older modeling studies, which would in turn affect the parameters used in the underlying disease … The MISCAN simulation program for the evaluation of screening for disease.

349. Therapies for Clinically Localized Prostate Cancer: Evidence Summary (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/prostate-cancer-therapies-summary.pdf
     September 01, 2020 - Mortality reductions may be limited to men age 65 and older and those with intermediate risk disease … slightly reduce mortality and metastases versus EBR alone in men with intermediate- and high-risk disease … the second leading cause of cancer death (33,330).1 In 90 percent of newly diagnosed cancers, the disease … Mortality differences may be limited to men age 65 and older or those with intermediate-risk disease … reduction due to RP may be limited to intermediate-risk disease or age <65 years.

350. Therapies for Clinically Localized Prostate Cancer: Evidence Summary (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/prostate-cancer-therapies-summary.pdf
     September 01, 2020 - Mortality reductions may be limited to men age 65 and older and those with intermediate risk disease … slightly reduce mortality and metastases versus EBR alone in men with intermediate- and high-risk disease … the second leading cause of cancer death (33,330).1 In 90 percent of newly diagnosed cancers, the disease … Mortality differences may be limited to men age 65 and older or those with intermediate-risk disease … reduction due to RP may be limited to intermediate-risk disease or age <65 years.

351. Troponin Cardiac Marker Interpretation During Renal Function Impairment | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/products/renal-function/research-protocol
     June 13, 2013 - chronic structural heart disease (e.g., coronary artery disease, heart failure, etc.), rather than acute … ; CHD = coronary heart disease; CKD = chronic kidney disease; ECG = electrocardiogram; ESRD = end-stage … Division of Kidney, Urologic, and Hematologic Diseases, National Institute of Diabetes and Digestive … and Kidney Diseases. … CHD = coronary heart disease CKD = chronic kidney disease cTn = cardiac-specific troponin ECG =

352. Renal-Function Research-Protocol (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/renal-function_research-protocol.pdf
     June 13, 2013 - ACS = acute coronary syndrome; CAD = coronary artery disease; CHD = coronary heart disease; CKD = chronic … National Institute of Diabetes and Digestive and Kidney Diseases, Division of Kidney, Urologic, and … Hematologic Diseases. … CHD = coronary heart disease CK = creatine kinase CKD = chronic kidney disease CT = computed tomography … kidney-disease-test-protocol.2 kidney-disease-test-protocol.3 kidney-disease-test-protocol.4 kidney-disease-test-protocol

353. Evidence Summary: Pharmacologic and Nonpharmacologic Therapies in Adult Patients With Exacerbation of COPD (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/cer-221-copd-evidence-summary.pdf
     October 01, 2019 - .1 In the United States, COPD affects approximately 15 million people; chronic lower respiratory diseases … Disease GIfCOL. … Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. … Airway clearance techniques for chronic obstructive pulmonary disease. … Chronic Obstructive Pulmonary Diseases. 2016 Feb 17;3(2):580-8. doi: https://dx.doi.org/10.15326/ jcopdf

354. Evidence Summary: Pharmacologic and Nonpharmacologic Therapies in Adult Patients With Exacerbation of COPD (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-221-copd-evidence-summary_0.pdf
     October 01, 2019 - .1 In the United States, COPD affects approximately 15 million people; chronic lower respiratory diseases … Disease GIfCOL. … Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. … Airway clearance techniques for chronic obstructive pulmonary disease. … Chronic Obstructive Pulmonary Diseases. 2016 Feb 17;3(2):580-8. doi: https://dx.doi.org/10.15326/ jcopdf

355. PULMONARY with "Discussions" in Exec Summary (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pulmonary-horizon-scan-high-impact-1306.pdf
     June 01, 2013 - Horizon Scanning System – Potential High-Impact Interventions Report Priority Area 13: Pulmonary Disease … Priority Area 13: Pulmonary Disease, Including Asthma Topic High-Impact Potential 1. … None of these approaches halt disease progression. … exacerbations, which may slow disease progression. … Chronic obstructive pulmonary disease.

356. Omega−3 Fatty Acids and Cardiovascular Disease: An Updated Systematic Review (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/fatty-acids-cardiovascular-disease_executive.pdf
     August 01, 2016 - oil supplements do not change one’s risk of several cardiovascular diseases (including overall major … macronutrient distribution range (a range of intakes that is associated with reduced risk of chronic diseases … Who are the participants (i.e., what is the population and setting of interest, including the diseases … (e.g., cancer, gastrointestinal disease, rheumatic disease, dialysis) Interventions/Exposures • … diagnosis o Cerebrovascular disease, new diagnosis o Peripheral vascular disease, new diagnosis

357. Transparency of Reporting Requirements: Omega-3 Fatty Acids and Cardiovascular Disease (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/transparency-omega-3_research-protocol.pdf
     September 02, 2016 - , rx, ui, tx, kw, ct, sh, bt, id, cc] n-3 B iom arkers 24. or/1-23 n-3 25. exp cardiovascular diseases … / C ardiovascular diseases, risk factors, adverse events 26. atherosclero$.mp. … , ot, ab, nm, hw, kw, kf, px, rx, ui, an, tx, sh, ct, bt, id, cc] 62. exp peripheral vascular diseases … (peripheral and vascular and disease$).mp. … (eg, cancer, gastrointestinal disease, dialysis, chronic renal failure, rheumatic disease) or condition

358. Omega-3 Fatty Acids and Cardiovascular Disease: An Updated Systematic Review (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/fatty-acids-cardiovascular-disease_disposition-comments.pdf
     August 12, 2016 - Omega-3 Fatty Acids and Cardiovascular Disease: An Updated Systematic Review Source: https://www.effectivehealthcare.ahrq.gov … Assessment Disposition of Comments Report Research Review Title: Omega-3 Fatty Acids and Cardiovascular Disease … Omega−3 Fatty Acids and Cardiovascular Disease: An Updated Systematic Review. … job was done in identifying the three major study populations: healthy adults without cardiovascular disease … appreciate the opportunity to provide comments on the draft report “Omega-3 Fatty Acids and Cardiovascular Disease

359. Effective Health Care (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/TND_0407_01-20-2011.pdf
     January 01, 2011 - Date: 3-23-11 1 Results of Topic Selection Process & Next Steps  Peripheral artery disease … intervention, and bypass surgery for improving health outcomes for patients with peripheral artery disease … Staff-Generated PICO Population(s): Adult patients with PAD and comorbid or multimorbid disease Intervention … endovascular intervention (PTA, stents) more effective than exercise therapy in Peripheral Artery Disease … )  PAD is a prevalent disease associated with an increased risk of cardiovascular events.

360. Treatment of Dementia Among Community-Dwelling and Institutionalized Medicare Beneficiaries | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/products/dementia-databases-methods/research
     May 22, 2008 - , devastating, and costly diseases affecting U.S. elderly residing in both community and long-term care … Alzheimer's disease was defined using the 331 code. … Rates of use were highest among those with a claim for Alzheimer's Disease. … The accuracy of medicare claims data in identifying Alzheimer's disease. … Lewy Body disease was not coded in 2002 and thus does not appear in our data.